本报记者 张晓玉 1月7日晚间，石家庄以岭药业股份有限公司（以下简称"以岭药业"）连续发布3份公告，全资子公司以 岭万洲的盐酸伐昔洛韦片获药品注册证书、全资孙公司衡水万洋的达格列净原料药上市申请获批、中药 新药芪龙定喘片临床试验申请获受理。三项成果分别覆盖抗病毒、糖尿病治疗、呼吸系统疾病三大治疗 领域。 添翼数字经济智库高级研究员吴婉莹对《证券日报》记者表示："以岭药业在抗病毒、糖尿病治疗及呼 吸系统疾病三大领域同步取得进展，体现了公司从中药优势领域向化药与创新中药多元拓展的战略布 局。这一系列突破反映了以岭药业依托研发平台推进产品矩阵多元化，逐步构建覆盖多治疗领域的综合 型药企格局，有助于提升其抗风险能力与长期竞争力。" 公告显示，本次获批的盐酸伐昔洛韦片，临床主要用于治疗带状疱疹、单纯疱疹病毒感染及预防复发。 作为《国家基本医疗保险、工伤保险和生育保险药品目录（2025年版）》乙类品种，该药物具备广阔的 市场需求基础。 米内网数据显示，2024年中国抗病毒药物市场规模达151.5亿元，伐昔洛韦系列产品占据3.17%的市场份 额，预计2025年该细分市场容量将达到4.5亿元，销售量有望突破1.3亿片。 公告 ...

Group 1 - Aoxiang Pharmaceutical has received approval from the National Medical Products Administration for the marketing of palbociclib and dagagliflozin active pharmaceutical ingredients [1] - Palbociclib is the first CDK4/6 inhibitor approved for cancer treatment, specifically for HR+ positive and HER2- negative locally advanced or metastatic breast cancer, with a projected global sales of approximately $4.367 billion in 2024 [1] - Dagagliflozin is a new oral hypoglycemic agent that can improve blood sugar control and reduce cardiovascular risks in heart failure patients, with an expected global sales of about $7.72 billion in 2024 [1] Group 2 - Aoxiang Pharmaceutical provides non-patent infringing process design, development, and regulatory submission services for generic drug manufacturers, gaining recognition in regulated markets like the US, Europe, and Japan [2] - The raw material drug sector is considered a core part of the pharmaceutical industry, with the quality of raw materials directly impacting the safety and efficacy of final drugs [2] - The trend of developing countries like China and India improving their raw material drug capabilities is evident, with advancements in research and production technology [2] Group 3 - R&D innovation is crucial for the sustainable development of pharmaceutical companies in China, especially in the face of challenges like patent expirations and centralized procurement [3] - Optimizing processes and enhancing quality for generic raw materials is essential for Chinese pharmaceutical companies to transition towards high-end specialty raw materials and innovative drugs [3]

Policy Developments - The National Health Commission and 13 other departments announced the "Five Health Promotion Action Plan" for children and adolescents, aiming to improve health in areas such as obesity, myopia, psychological behavior abnormalities, spinal deformities, and dental caries by 2026-2030 [2] Drug and Medical Device Approvals - Aosheng Pharmaceutical received approval for the market launch of the raw materials for Palbociclib and Dapagliflozin, which will enhance the company's product line and competitiveness [4] - Aied Biological obtained a medical device registration certificate for its BRCA1/BRCA2 gene mutation detection kit for prostate cancer, marking the first approval for this indication in China [5] Capital Markets - Yingsi Intelligent successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 2.277 billion, becoming the first AI-driven biopharmaceutical company to list under the main board rules [7] - China Pharmaceutical announced a plan to acquire 70% of Shanghai Zezheng Pharmaceutical for RMB 525 million, focusing on improved drug development services [8] - Yuekang Pharmaceutical submitted an application for H-share issuance to the Hong Kong Stock Exchange [9] Industry Events - Guangdong Province will implement a "one registration for three days" policy in public medical institutions starting January 1, 2026, allowing patients to return for follow-up consultations without additional registration fees within three days [11] Company Developments - Jincheng Pharmaceutical signed a supplementary agreement regarding tax payment responsibilities with shareholders, clarifying compensation terms related to tax liabilities [12] - *ST Chang Pharmaceutical faced a court ruling rejecting its restructuring application, leading to the bankruptcy of its subsidiary and potential delisting risks due to financial misconduct investigations [14]

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

Core Viewpoint - The approval of the raw materials for Palbociclib and Dapagliflozin indicates compliance with national drug registration requirements, enhancing the company's product line and competitiveness, and promoting sustainable and healthy development [2]. Group 1: Product Approvals - The company received the approval notice for the raw materials of Palbociclib and Dapagliflozin from the National Medical Products Administration [1]. - Palbociclib is a CDK4/6 inhibitor used for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - Dapagliflozin is an SGLT-2 inhibitor used for improving blood sugar control and reducing cardiovascular risks in adults with heart failure [1]. Group 2: Strategic Implications - The approval of these raw materials will enrich the company's product line, enhancing its competitiveness in the pharmaceutical market [2]. - The introduction of these drugs is expected to contribute to the company's continuous, stable, and healthy development [2].

Core Viewpoint - Aoxiang Pharmaceutical (603229) has received approval from the National Medical Products Administration for the marketing of its active pharmaceutical ingredients, Palbociclib and Dapagliflozin [1] Group 1 - The company announced the receipt of the approval notice for the marketing application of Palbociclib and Dapagliflozin [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of two active pharmaceutical ingredients: Palbociclib and Dapagliflozin [1] Group 1: Product Approvals - Palbociclib is a CDK4/6 inhibitor indicated for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer [1] - Dapagliflozin is a novel oral hypoglycemic agent classified as an SGLT-2 inhibitor, which can be used as monotherapy or in combination therapy to improve blood glucose control based on diet and exercise [1]

Core Viewpoint - The company is focused on expanding its CDMO services and developing innovative biopharmaceuticals, with significant investments in R&D and strategic partnerships to enhance its product offerings and market presence [1][6][7]. Company Overview - The company provides key pharmaceutical intermediates and raw material CDMO services to multinational pharmaceutical companies and research institutions, with a focus on various therapeutic areas including antiviral, oncology, and cardiovascular diseases [1][2]. - The company has established a subsidiary, Jiuqian Cheng Bio, to enter the biopharmaceutical sector, particularly in cell therapy [4][6]. R&D Investment - The company invested CNY 93.71 million in R&D, accounting for 28.13% of its revenue, representing a 241.20% increase year-on-year [5]. - The company has developed several advanced technology platforms for drug synthesis and is enhancing its capabilities in high-end raw material and formulation development [5]. Market Expansion - The company is actively developing its market presence by participating in major industry exhibitions and strengthening relationships with international pharmaceutical companies [7]. - The company aims to become a significant small molecule CDMO service provider in China, offering comprehensive lifecycle services to global innovative drug clients [7]. Talent Development - The company has a workforce of 607 employees, with a significant proportion holding advanced degrees, and has increased its R&D personnel by 36.26% [9]. - The company emphasizes a comprehensive training system to enhance employee skills and support its strategic goals [9]. Project Investment - The company is upgrading its production facilities to improve efficiency and reduce costs, with new projects expected to add 519,000 liters of production capacity [10]. - The company is also focusing on energy-saving technologies and green production methods to enhance sustainability [10]. Quality Management - The company has undergone 26 quality audits and has maintained compliance with various regulatory inspections, ensuring a robust quality management system [10][11]. - The company has integrated safety and environmental management into its core operations, receiving recognition for its green development initiatives [11]. Strategic Partnerships - The company has entered into a collaboration with Chiron Pharma for cell therapy projects, with a total project value of USD 17 million, focusing on heart and brain stroke treatments [6][13]. - The projects have received FDA clinical approvals, with ongoing clinical trials in the U.S. and plans for implementation in China [6][13][14].